Open AccessTolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age
Author(s) -
Ii Betuela,
Quique Bassat,
Benson Kiniboro,
Leanne J. Robinson,
Anna RosanasUrgell,
Danielle I. Stanisic,
Peter M. Siba,
Pedro L. Alonso,
Ivo Müeller
Publication year - 2012
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.05566-11
Subject(s) - primaquine , tolerability , plasmodium vivax , chloroquine , medicine , malaria , glucose 6 phosphate dehydrogenase , drug , pharmacology , pediatrics , adverse effect , biology , immunology , plasmodium falciparum , dehydrogenase , biochemistry , enzyme
Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom